Human Fibroblast-Like Synoviocytes: HFLS 人類纖維母細胞樣滑膜細胞：HFLS
產品型號： 408K-05a
Human Fibroblast-Like Synoviocytes (HFLS) provide an excellent cellular model for studying the normal and pathological physiology of synoviocytes and development of joint diseases.
Normal HFLS from Cell Applications, Inc. have been used to examine:
- TNFα – mediated changes in gene expression
- TNF-like weak inducer of apoptosis (TWEAK) contribution to joint inflammation by inducing chemokines and matrix metalloprotease-9, suggesting TWEAK as a new therapeutic target
- The role of miR-124a in arthritis pathogenesis
- C/EBPβ regulation of metalloproteinases and ADAMTS family members in synoviocytes stimulated with IL-1β
- HMW-HA suppression of ADAMTS4 mRNA and protein expression via CD44, p38 MAPK and JNK pathways
- Anti-inflammatory and antirheumatic activity of various compounds, such as NF-κB inhibitors, AGIX-4207, HA–methotrexate conjugates and bucillamine
- Reactive arthritis triggered by chlamydial infection
- Mechanisms of arthritis-like syndrome in patients infected with chikungunya (CHIK) virus
- Use of Leukocyte-poor, RBC-free platelet-rich plasma in clinical orthopaedics, because leukocytes and RBCs cause synoviocyte death and proinflammatory mediator production
- Cartilage link protein and MAGP2 as markers to distinguish chondrocytes and synovial cells
- Creation of induced pluripotent stem cells (iPSC) by using the now classic “Yamanaka cocktail”, the discovery for which Dr. Shinya Yamanaka was awarded the Nobel Prize in 2012
- Causative agents, immunopathological mechanisms and signal transduction pathways leading to joint inflammation in rheumatoid arthritis
- The role of estrogen signaling in increasing inflammation
- Anti-inflammatory properties of herbal compound Sinomenine suggested for rheumatoid arthritis treatment
- Effects of extracellular matrix composition on cell attachment and migration relevant to T-cell function in inflamed tissues
- The role of human endogenous retroviruses (HERVs) in development of rheumatoid arthritis
- Activated expression of different forms of HERV, contributing to development of rheumatoid arthritis symptoms by different mechanisms
DETAILS
|
Tissue
|
Normal healthy human synovial tissue
|
|
QC
|
No bacteria, yeast, fungi, mycoplasma, virus
|
|
Bioassay
|
Attach, spread, proliferate in Growth Med
|
|
Cryovial
|
500,000 HFLS (2nd passage) frozen in Basal Medium w/ 10% FBS, 10% DMSO
|
|
Kit
|
Cryovial frozen HFLS (408-05a), Growth Medium (415-500), Subcltr Rgnt Kit (090K)
|
|
Proliferating
|
Shipped in Gr Med, 3rd psg (flasks or plates)
|
|
Doublings
|
At least 5
|
|
Applications
|
Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use.
|
PRODUCT
| PRODUCT | SIZE | CAT.# |
| Cryopreserved HFLS, Adult: 5x10^5 Cells (Adult), Medium & Subculture Reagents (See Details tab for specifics). | 1 Kit | 408K-05a |
| Cryopreserved HFLS, Adult: Frozen HFLS (5x10^5). | 1 Cryovial | 408-05a |
| Proliferating HFLS, Adult: Actively growing, dividing cells in medium. Estimated release June 2021. | T-25 Flask | 409-25a |
| Proliferating HFLS, Adult: Actively growing, dividing cells in medium. Estimated release June 2021. | T-75 Flask | 409-75a |
RELATED PRODUCTS
| PRODUCT | SIZE | CAT.# |
| HFLS Growth Medium: All-in-one ready-to-use | 500 ml | 415-500 |
| HFLS Growth Medium Kit: Basal medium & growth supplement sold together packaged separately | Yields 500 ml | 415K-500 |
| HFLS Basal Medium: Basal medium (contains no growth supplement). Add GS before use. | 500 ml | 414-500 |
| HFLS Growth Supplement: Added to Basal Medium to create Growth Medium | 50 ml | 415-GS |
| HFLS Growth Medium wo Antibiotics: Growth medium without antibiotics | 500 ml | 415A-500 |
| HFLS Growth Medium wo FBS: Growth medium without FBS | 500 ml | 415F-500 |
EXTENDED FAMILY PRODUCTS
| PRODUCT | SIZE | CAT.# |
| HFLS RNA, Adult: Total RNA prepared from Human Fibroblast-Like Synoviocytes, adult | 10 ug | 408-R10a |
| HFLS RNA, Adult: Total RNA prepared from Human Fibroblast-Like Synoviocytes, adult | 25 ug | 408-R25a |
Inline content